These findings emphasized that SETD2 deficiency inhibits the proliferation and migration of HCC cells through decreasing the H3K36me3 level on the FGFBP1 gene body through the FGF-FGFR-ERK axis. Here, SETD2 is linked to hepatocellular carcinoma.